The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple sclerosis.

A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

"Our decision to treat typically needs to be made on the balance of likelihood, before the diagnosis of an associated disease process can be fully established, with definitive tests for multiple ...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...

Riad Sherif, M.D., Chief Executive Officer of Oculis, commented: “It is a privilege to collaborate with Pitié-Salpêtrière Hospital, a world-renowned center for modern neurology, on the Phase 2 ACUITY ...